Comparing two tacrolimus drugs in kidney transplant patients
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older) getting a first or second kidney from a living or deceased donor.
- Your blood type is compatible with the donor kidney.
- You can swallow tablets or capsules.
- You have not had any other organ transplant (like liver or heart).
- You do not have active infections like hepatitis B, C, or HIV.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
This study compares immediate-release versus extended-release tacrolimus (an anti-rejection medicine) to see if one form causes fewer tremors after a first liver transplant. It may help you and your care team choose the best form if tremors are a problem while your body adjusts after transplant.
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
This trial looks at whether changing your maintenance anti-rejection medicine from Prograf (usually twice daily) to Envarsus (once daily) can help keep your liver and kidney function stable. It targets people who may be having kidney side effects, symptoms from tacrolimus, or trouble taking a twice-daily medicine.
This non-interventional study looks at how tacrolimus blood levels relate to transplant effectiveness and side effects. It uses your existing medical data to understand whether tacrolimus behaves differently from person to person and how that links to safety.
This trial studies whether taking an extended-release form of tacrolimus (a medicine to prevent transplant rejection) after a liver transplant works well for people who are followed at the University of Alberta. It may help simplify dosing and monitor safety and effectiveness after transplant.
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.